Cargando…

A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health

PURPOSE: Our purpose was to examine the effects of 2 yr of creatine monohydrate supplementation and exercise on bone health in postmenopausal women. METHODS: Two hundred and thirty-seven postmenopausal women (mean age, 59 yr) were randomized to receive creatine (0.14 g·kg(−1)·d(−1)) or placebo durin...

Descripción completa

Detalles Bibliográficos
Autores principales: CHILIBECK, PHILIP D., CANDOW, DARREN G., GORDON, JULIANNE J., DUFF, WHITNEY R. D., MASON, RILEY, SHAW, KEELY, TAYLOR-GJEVRE, REGINA, NAIR, BINDU, ZELLO, GORDON A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487398/
https://www.ncbi.nlm.nih.gov/pubmed/37144634
http://dx.doi.org/10.1249/MSS.0000000000003202
_version_ 1785103230136483840
author CHILIBECK, PHILIP D.
CANDOW, DARREN G.
GORDON, JULIANNE J.
DUFF, WHITNEY R. D.
MASON, RILEY
SHAW, KEELY
TAYLOR-GJEVRE, REGINA
NAIR, BINDU
ZELLO, GORDON A.
author_facet CHILIBECK, PHILIP D.
CANDOW, DARREN G.
GORDON, JULIANNE J.
DUFF, WHITNEY R. D.
MASON, RILEY
SHAW, KEELY
TAYLOR-GJEVRE, REGINA
NAIR, BINDU
ZELLO, GORDON A.
author_sort CHILIBECK, PHILIP D.
collection PubMed
description PURPOSE: Our purpose was to examine the effects of 2 yr of creatine monohydrate supplementation and exercise on bone health in postmenopausal women. METHODS: Two hundred and thirty-seven postmenopausal women (mean age, 59 yr) were randomized to receive creatine (0.14 g·kg(−1)·d(−1)) or placebo during a resistance training (3 d·wk(−1)) and walking (6 d·wk(−1)) program for 2 yr. Our primary outcome was the femoral neck bone mineral density (BMD), with lumbar spine BMD and proximal femur geometric properties as the secondary outcomes. RESULTS: Compared with placebo, creatine supplementation had no effect on BMD of the femoral neck (creatine: 0.725 ± 0.110 to 0.712 ± 0.100 g·cm(−2); placebo: 0.721 ± 0.102 to 0.706 ± 0.097 g·cm(−2)), total hip (creatine: 0.879 ± 0.118 to 0.872 ± 0.114 g·cm(−2); placebo: 0.881 ± 0.111 to 0.873 ± 0.109 g·cm(−2)), or lumbar spine (creatine: 0.932 ± 0.133 to 0.925 ± 0.131 g·cm(−2); placebo: 0.923 ± 0.145 to 0.915 ± 0.143 g·cm(−2)). Creatine significantly maintained section modulus (1.35 ± 0.29 to 1.34 ± 0.26 vs 1.34 ± 0.25 to 1.28 ± 0.23 cm(3) (placebo), P = 0.0011), predictive of bone bending strength, and buckling ratio (10.8 ± 2.6 to 11.1 ± 2.2 vs 11.0 ± 2.6 to 11.6 ± 2.7 (placebo), P = 0.011), predictive of reduced cortical bending under compressive loads, at the narrow part of the femoral neck. Creatine reduced walking time over 80 m (48.6 ± 5.6 to 47.1 ± 5.4 vs 48.3 ± 4.5 to 48.2 ± 4.9 s (placebo), P = 0.0008) but had no effect on muscular strength (i.e., one-repetition maximum) during bench press (32.1 ± 12.7 to 42.6 ± 14.1 vs 30.6 ± 10.9 to 41.4 ± 14 kg (placebo)) and hack squat (57.6 ± 21.6 to 84.4 ± 28.1 vs 56.6 ± 24.0 to 82.7 ± 25.0 kg (placebo)). In the subanalysis of valid completers, creatine increased lean tissue mass compared with placebo (40.8 ± 5.7 to 43.1 ± 5.9 vs 40.4 ± 5.3 to 42.0 ± 5.2 kg (placebo), P = 0.046). CONCLUSIONS: Two years of creatine supplementation and exercise in postmenopausal women had no effect on BMD; yet, it improved some bone geometric properties at the proximal femur.
format Online
Article
Text
id pubmed-10487398
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104873982023-09-09 A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health CHILIBECK, PHILIP D. CANDOW, DARREN G. GORDON, JULIANNE J. DUFF, WHITNEY R. D. MASON, RILEY SHAW, KEELY TAYLOR-GJEVRE, REGINA NAIR, BINDU ZELLO, GORDON A. Med Sci Sports Exerc Clinical Sciences PURPOSE: Our purpose was to examine the effects of 2 yr of creatine monohydrate supplementation and exercise on bone health in postmenopausal women. METHODS: Two hundred and thirty-seven postmenopausal women (mean age, 59 yr) were randomized to receive creatine (0.14 g·kg(−1)·d(−1)) or placebo during a resistance training (3 d·wk(−1)) and walking (6 d·wk(−1)) program for 2 yr. Our primary outcome was the femoral neck bone mineral density (BMD), with lumbar spine BMD and proximal femur geometric properties as the secondary outcomes. RESULTS: Compared with placebo, creatine supplementation had no effect on BMD of the femoral neck (creatine: 0.725 ± 0.110 to 0.712 ± 0.100 g·cm(−2); placebo: 0.721 ± 0.102 to 0.706 ± 0.097 g·cm(−2)), total hip (creatine: 0.879 ± 0.118 to 0.872 ± 0.114 g·cm(−2); placebo: 0.881 ± 0.111 to 0.873 ± 0.109 g·cm(−2)), or lumbar spine (creatine: 0.932 ± 0.133 to 0.925 ± 0.131 g·cm(−2); placebo: 0.923 ± 0.145 to 0.915 ± 0.143 g·cm(−2)). Creatine significantly maintained section modulus (1.35 ± 0.29 to 1.34 ± 0.26 vs 1.34 ± 0.25 to 1.28 ± 0.23 cm(3) (placebo), P = 0.0011), predictive of bone bending strength, and buckling ratio (10.8 ± 2.6 to 11.1 ± 2.2 vs 11.0 ± 2.6 to 11.6 ± 2.7 (placebo), P = 0.011), predictive of reduced cortical bending under compressive loads, at the narrow part of the femoral neck. Creatine reduced walking time over 80 m (48.6 ± 5.6 to 47.1 ± 5.4 vs 48.3 ± 4.5 to 48.2 ± 4.9 s (placebo), P = 0.0008) but had no effect on muscular strength (i.e., one-repetition maximum) during bench press (32.1 ± 12.7 to 42.6 ± 14.1 vs 30.6 ± 10.9 to 41.4 ± 14 kg (placebo)) and hack squat (57.6 ± 21.6 to 84.4 ± 28.1 vs 56.6 ± 24.0 to 82.7 ± 25.0 kg (placebo)). In the subanalysis of valid completers, creatine increased lean tissue mass compared with placebo (40.8 ± 5.7 to 43.1 ± 5.9 vs 40.4 ± 5.3 to 42.0 ± 5.2 kg (placebo), P = 0.046). CONCLUSIONS: Two years of creatine supplementation and exercise in postmenopausal women had no effect on BMD; yet, it improved some bone geometric properties at the proximal femur. Lippincott Williams & Wilkins 2023-10 2023-05-05 /pmc/articles/PMC10487398/ /pubmed/37144634 http://dx.doi.org/10.1249/MSS.0000000000003202 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American College of Sports Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Clinical Sciences
CHILIBECK, PHILIP D.
CANDOW, DARREN G.
GORDON, JULIANNE J.
DUFF, WHITNEY R. D.
MASON, RILEY
SHAW, KEELY
TAYLOR-GJEVRE, REGINA
NAIR, BINDU
ZELLO, GORDON A.
A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health
title A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health
title_full A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health
title_fullStr A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health
title_full_unstemmed A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health
title_short A 2-yr Randomized Controlled Trial on Creatine Supplementation during Exercise for Postmenopausal Bone Health
title_sort 2-yr randomized controlled trial on creatine supplementation during exercise for postmenopausal bone health
topic Clinical Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487398/
https://www.ncbi.nlm.nih.gov/pubmed/37144634
http://dx.doi.org/10.1249/MSS.0000000000003202
work_keys_str_mv AT chilibeckphilipd a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT candowdarreng a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT gordonjuliannej a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT duffwhitneyrd a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT masonriley a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT shawkeely a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT taylorgjevreregina a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT nairbindu a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT zellogordona a2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT chilibeckphilipd 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT candowdarreng 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT gordonjuliannej 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT duffwhitneyrd 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT masonriley 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT shawkeely 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT taylorgjevreregina 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT nairbindu 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth
AT zellogordona 2yrrandomizedcontrolledtrialoncreatinesupplementationduringexerciseforpostmenopausalbonehealth